News

Pure Extracts Receives 3 New Listings from the Ontario Cannabis Store

VANCOUVER, British Columbia., May 31, 2022 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure…

2 years ago

Helius Medical Announces Poster to Be Presented at the Consortium for Multiple Sclerosis Centers (CMSC) Annual Conference

NEWTOWN, Pa., May 31, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech…

2 years ago

Virax Biolabs Announces the Formation of Advisory Board of Industry Leaders

London, United Kingdom, May 31, 2022 (GLOBE NEWSWIRE) -- Virax Biolabs Group Limited  (“Virax” or the “Company”), an innovative biotechnology…

2 years ago

Veru to Present Three Presentations at the 2022 American Society for Clinical Oncology Annual Meeting on June 3-7

MIAMI, May 31, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for…

2 years ago

Galecto to Participate at Jefferies Healthcare Conference

BOSTON, May 31, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development…

2 years ago

Agenus Advances Portfolio with 6 Clinical Collaborations

LEXINGTON, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of…

2 years ago

Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United States

Dotinurad is a potential best-in-class urate transporter (URAT1) inhibitor in clinical development at Fortress’ subsidiary company, UR-1 Therapeutics Dotinurad (URECE®…

2 years ago

180 Life Sciences Begins Consultations with UK and US Regulatory Authorities on Pathway for a Therapy that Could Prevent Progression of Early-Stage Dupuytren’s Disease

PALO ALTO, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the…

2 years ago

ChemoCentryx Announces Changes to its Board of Directors

-- David E. Wheadon, M.D., Elected to the Board as an Independent Director -- -- Henry A. McKinnell, Jr., to…

2 years ago

SciSparc to Collaborate with Polyrizon for Brain Targeting Using Intranasal Hydrogel Systems

SciSparc will use its SCI-160 technology platform for treating pain in combination with Polyrizons' Trap and TargetTM technology TEL AVIV,…

2 years ago